A patent has been filed for the use of cannabis therapies for the manipulation of ion channels in sensory neurons that contribute to chronic pain, peripheral neuropathy, urinary cystitis, asthma, and specific types of hearing loss.
The designation has been given to Revive Therapeutics for the use of CBD in treating autoimmune hepatitis.
As the California cannabis industry evolves and state-mandated laboratory standards of operation prove vital, both clients and consumers will now have assurance that the results will be accurate and reliable.
Epidiolex contains cannabidiol (CBD) and is the first FDA-approved drug that contains a purified drug substance derived from marijuana.
The standard will outline best lab practices, recommended certifications, various types of analyses, and the quality assurance functions for labs working with cannabis.
Studies have already shown that phytocannabinoids like cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior.
These findings reopen the discussion about the ability of other phytocannabinoids, whose mechanism of action was unknown, to bind directly to cannabinoid receptors as Δ 9-THC does.
The research is focused on developing a drug that enables patients to benefit from the medicinal benefits of THC without experiencing its inherit psychoactive properties.